Research ArticleClinical Studies

Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study

SHUNSUKE TATSUKI, TADAHIRO SHOJI, MARINA ABE, HIDETOSHI TOMABECHI, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, TAKESHI AIDA and TSUKASA BABA
Anticancer Research September 2022, 42 (9) 4603-4610; DOI: https://doi.org/10.21873/anticanres.15964

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Kaplan-Meier curve for investigator-assessed progression-free survival (PFS) (A) and overall survival (OS) (B). The median PFS and OS were 8.5 months and 35.8 months, respectively. MST, Median survival time; CI, confidence interval.

  • Figure 2.
    Figure 2.

    Kaplan-Meier curve comparing overall survival (OS) in PFI ≥12 months and <12 months. The median OS of the groups with PFI ≥12 months and <12 months were 41 months and 21.8 months, respectively, with statistically significant differences (HR=0.34, 95% CI=0.14-0.83, p=0.0128). PFI, Platinum-free interval; MST, median survival time; HR, hazard ratio; CI, confidence interval.

Tables

  • Table I.
  • Table II.
  • Table III.
  • Table IV.
  • Table V.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study
SHUNSUKE TATSUKI, TADAHIRO SHOJI, MARINA ABE, HIDETOSHI TOMABECHI, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, TAKESHI AIDA, TSUKASA BABA
Anticancer Research Sep 2022, 42 (9) 4603-4610; DOI: 10.21873/anticanres.15964
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords